JD Supra21h
European Commission Approves Celltrion’s AVTOZMA (CT-P47)
AVTOZMA® is Celltrion’s twelfth biosimilar to obtain marketing authorization in the European Union. Stay tuned to Big Molecule Watch for more regulatory updates on biosimilars.
Contract Pharma1d
FDA Approves Celltrion’s Biosimilars Referencing Prolia and Xgeva
The U.S. Food and Drug Administration (FDA) has approved Celltrion’s Stoboclo (CT-P41, denosumab-bmwo) and Osenvelt (CT-P41, ...
Celltrion's bone disease biosimilars get approval in US
Celltrion, a major South Korean biopharmaceutical firm, said on Tuesday its two new bio-similars for bone disease treatment ...
Daijiworld1d
Celltrion’s bone disease biosimilars secure FDA approval for US market
South Korean biopharmaceutical giant Celltrion announced on Tuesday that its two new biosimilars for bone disease treatment have received approval from the United States Food and Drug Administration ...
manilatimes1d
Celltrion receives U.S. FDA approval for STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) biosimilars referencing PROLIA® and XGEVA®
STOBOCLO ® (denosumab-bmwo) and OSENVELT ® (denosumab-bmwo) are approved by FDA for all indications of reference products ...
PMLiVE6d
EC approves Celltrion’s RoActemra biosimilar Avtozma for inflammatory diseases
Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody ...